Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


SmileCity Healthcare all smiles over DtCA decision

Tuesday, 12 December 2006

SmileCity Healthcare all smiles over DtCA decision

SmileCity welcomes the Government’s decision to continue supporting Direct to Consumer Advertising (DtCA) for prescription medicines.

SmileCity is a permission based online rewards programme that gives its members “SmileCity points” for every email they receive direct from health care marketers. These points can then be converted to cash, donated to charity or used to bid in SmileCity’s online auctions.

Launched in May, SmileCity Healthcare ( has attracted 25,347 New Zealand members that have opted to receive information direct to their inbox from marketers of prescription and non-prescription medicines.

Tom Skotidas, Sales and Marketing Director of SmileCity, says the Government’s decision is a positive step for New Zealand’s reputation in the pharmaceutical industry worldwide.

“New Zealand has led the world when it comes to innovative marketing solutions for prescription medicines.

“The decision reached is common sense, and we applaud the Government for allowing New Zealand to continue creating innovative touch points for marketers to reach consumers,” he says.

One of the key benefits of SmileCity Healthcare for members is tailored information to suit their health interests.

At the time of signing up members are asked which healthcare topics they are interested in from a list including asthma, hayfever, diabetes and many more. They then receive tailored messages from healthcare companies with products and services that relate directly to these areas of health.

On the back of this decision, SmileCity Healthcare is looking to attract more in-house pharmaceutical marketers or agency representatives that would like to communicate directly with consumers about their health care products and promotions.



About SmileCity Healthcare

SmileCity Healthcare is a first in New Zealand for consumers who are interested in receiving health-related information and offers direct to their inbox. When consumers join SmileCity Healthcare they give SmileCity permission to send them information and offers from New Zealand’s leading healthcare organisations and companies. All SmileCity Healthcare emails are carefully screened to ensure they comply with New Zealand laws and regulations.

© Scoop Media

Business Headlines | Sci-Tech Headlines


57 Million Users' Data: Uber Breach "Utterly Preventatable"

Cybersecurity leader Centrify says the Uber data breach of 57 million customer and driver records - which the ride-hailing company hid for more than a year - was “utterly preventable”. More>>

Scoop 3.0: How You Can Help Scoop’s Evolution

We have big plans for 2018 as we look to expand our public interest journalism coverage, upgrade our publishing infrastructure and offer even more valuable business tools to commercial users of Scoop. More>>

Having A Cow? Dairy Product Prices Slide For Fourth Straight Auction

Dairy product prices fell at the Global Dairy Trade auction, retreating for the fourth straight auction amid signs of increased production... Whole milk powder fell 2.7 percent to US$2,778 a tonne. More>>


Statistics: Butter At Record $5.67/Block; High Vegetable Prices

Rising dairy prices have pushed food prices up 2.7 percent in the year to October 2017, Stats NZ said today. This followed a 3.0 percent increase in the year to September 2017. More>>


Science: New Research Finds Herbicides Cause Antibiotic Resistance

New University of Canterbury research confirms that the active ingredients of the commonly used herbicides, RoundUp, Kamba and 2,4-D (glyphosate, dicamba and 2,4-D, respectively), each alone cause antibiotic resistance at concentrations well below label application rates. More>>


CO2 And Water: Fonterra (And Dairy NZ)'s Environment Plans

Federated Farmers support Fonterra’s bold push to get to zero emissions of CO2 on the manufacturing side of the Co-operative, both in New Zealand and across its global network. More>>